Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025
The amount of water a person needs each day varies based on factors such as age, activity level, and overall health
Chronic diarrhea persisting beyond four weeks, even if mild, requires investigation to exclude conditions such as microscopic colitis, bile acid malabsorption, or exocrine pancreatic insufficiency
Research shows that GLP-1 receptor-like signals are present in colon nerves and elevated in irritable bowel syndrome (IBS) patients, possibly explaining the presence of more nerve fibers in their colon [106]
Side effect comparison table The bottom line on safety: cagrilintide alone has a milder side effect profile